Sanofi-Aventis Acomplia (correction)
Executive Summary
In a June 5 story on Sanofi-Aventis' incoming CEO Gerard Le Fur, "The Pink Sheet" incorrectly described the company's pending product Acomplia (rimonabant) as approved for weight loss. Acomplia was deemed "approvable" for weight loss and "not approvable" for smoking cessation in February (1"The Pink Sheet" Feb. 27, 2006, p. 4)...